Integra LifeSciences Holdings (IART) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integra LifeSciences Holdings (IART) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($40.91 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Integra LifeSciences Holdings - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Integra LifeSciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Integra LifeSciences Holdings for a breakdown of total debt and financial obligations.
Integra LifeSciences Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integra LifeSciences Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
0.025x |
|
Ottogi
KO:007310
|
0.057x |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA
|
-0.008x |
|
Omada Health, Inc. Common Stock
NASDAQ:OMDA
|
0.047x |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
-0.026x |
|
Omeros Corporation
NASDAQ:OMER
|
0.084x |
|
Artis Real Estate Investment Trust
TO:AX-UN
|
0.040x |
|
Yijiahe Technology Co Ltd
SHG:603666
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Integra LifeSciences Holdings (1995–2024)
The table below shows the annual cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see Integra LifeSciences Holdings (IART) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.55 Billion | $129.38 Million | 0.084x | -5.01% |
| 2023-12-31 | $1.59 Billion | $139.96 Million | 0.088x | -39.86% |
| 2022-12-31 | $1.80 Billion | $264.47 Million | 0.147x | -20.96% |
| 2021-12-31 | $1.68 Billion | $312.43 Million | 0.185x | +37.82% |
| 2020-12-31 | $1.51 Billion | $203.83 Million | 0.135x | -17.63% |
| 2019-12-31 | $1.42 Billion | $231.43 Million | 0.163x | +12.55% |
| 2018-12-31 | $1.38 Billion | $199.68 Million | 0.145x | +21.93% |
| 2017-12-31 | $962.31 Million | $114.54 Million | 0.119x | -14.14% |
| 2016-12-31 | $839.67 Million | $116.41 Million | 0.139x | +10.26% |
| 2015-12-31 | $751.44 Million | $94.48 Million | 0.126x | +11.45% |
| 2014-12-31 | $704.32 Million | $79.46 Million | 0.113x | +41.94% |
| 2013-12-31 | $670.18 Million | $53.27 Million | 0.079x | -29.91% |
| 2012-12-31 | $517.77 Million | $58.72 Million | 0.113x | -46.45% |
| 2011-12-31 | $492.64 Million | $104.33 Million | 0.212x | +0.29% |
| 2010-12-31 | $499.96 Million | $105.57 Million | 0.211x | -34.41% |
| 2009-12-31 | $444.88 Million | $143.24 Million | 0.322x | +55.33% |
| 2008-12-31 | $350.21 Million | $72.59 Million | 0.207x | +14.79% |
| 2007-12-31 | $260.43 Million | $47.03 Million | 0.181x | -25.42% |
| 2006-12-31 | $296.16 Million | $71.70 Million | 0.242x | +23.43% |
| 2005-12-31 | $289.82 Million | $56.85 Million | 0.196x | +54.92% |
| 2004-12-31 | $307.82 Million | $38.98 Million | 0.127x | -2.37% |
| 2003-12-31 | $268.53 Million | $34.83 Million | 0.130x | +0.39% |
| 2002-12-31 | $247.60 Million | $31.98 Million | 0.129x | +67.89% |
| 2001-12-31 | $204.06 Million | $15.70 Million | 0.077x | +183.43% |
| 2000-12-31 | $53.78 Million | $-4.96 Million | -0.092x | -240.18% |
| 1999-12-31 | $38.00 Million | $2.50 Million | 0.066x | +121.08% |
| 1998-12-31 | $31.40 Million | $-9.80 Million | -0.312x | -41.43% |
| 1997-12-31 | $35.80 Million | $-7.90 Million | -0.221x | -27.99% |
| 1996-12-31 | $46.40 Million | $-8.00 Million | -0.172x | +46.43% |
| 1995-12-31 | $17.40 Million | $-5.60 Million | -0.322x | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural r… Read more